TipRanks
Collegium Pharmaceutical (DE:354)
FRANKFURT:354
Germany Market
354
Collegium Pharmaceutical
RESEARCH TOOLSreports

Collegium Pharmaceutical (354) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

354 Analyst Ratings

Strong Buy
6Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Collegium
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

354 Stock 12 Month Forecast

Average Price Target

€42.24
▲(90.26% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Collegium Pharmaceutical in the last 3 months. The average price target is €42.24 with a high forecast of €52.25 and a low forecast of €37.45. The average price target represents a 90.26% change from the last price of €22.20.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"€19","36":"€36","53":"€53","27.5":"€27.5","44.5":"€44.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52.251609,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€52.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.236717275,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€42.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.44698645,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€37.45</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,27.5,36,44.5,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.8,23.219354538461538,25.638709076923078,28.05806361538462,30.477418153846155,32.89677269230769,35.31612723076923,37.73548176923077,40.15483630769231,42.574190846153854,44.99354538461539,47.41289992307692,49.83225446153847,{"y":52.251609,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.8,22.448978251923076,24.097956503846156,25.74693475576923,27.395913007692307,29.044891259615383,30.69386951153846,32.342847763461535,33.99182601538462,35.640804267307686,37.28978251923077,38.938760771153845,40.58773902307692,{"y":42.236717275,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.8,22.08053741923077,23.36107483846154,24.64161225769231,25.922149676923077,27.202687096153845,28.483224515384613,29.763761934615385,31.044299353846153,32.324836773076925,33.60537419230769,34.88591161153846,36.16644903076923,{"y":37.44698645,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.8,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€52.25Average Price Target€42.24Lowest Price Target€37.45
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:354
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
€52.25
Buy
135.37%
Upside
Reiterated
09/21/26
H.C. Wainwright Reaffirms Their Buy Rating on Collegium Pharmaceutical (COLL)
Leerink Partners Analyst forecast on DE:354
Daniel Clark
Leerink Partners
Leerink Partners
€39.19
Buy
76.53%
Upside
Initiated
09/09/26
Leerink bullish on Collegium Pharmaceutical, initiates with an OutperformLeerink bullish on Collegium Pharmaceutical, initiates with an Outperform
Truist Financial Analyst forecast on DE:354
Alexander Xenakis
Truist Financial
Not Ranked
Truist Financial
€50.51→€42.67
Buy
92.22%
Upside
Initiated
09/09/26
Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (NASDAQ: COLL), Revolution Medicines (NASDAQ: RVMD) and Intellia Therapeutics (NASDAQ: NTLA)
Barclays Analyst forecast on DE:354
Jenna Davidner
Barclays
Barclays
€48.77→€41.8
Buy
88.29%
Upside
Reiterated
08/18/26
Barclays Sticks to Their Buy Rating for Collegium Pharmaceutical (COLL)
Piper Sandler Analyst forecast on DE:354
David Amsellem
Piper Sandler
Piper Sandler
€39.19→€37.45
Hold
68.68%
Upside
Reiterated
08/07/26
Piper Sandler Sticks to Their Hold Rating for Collegium Pharmaceutical (COLL)
Needham Analyst forecast on DE:354
Serge Belanger
Needham
Needham
€48.77→€40.06
Buy
80.45%
Upside
Reiterated
08/06/26
Analysts' Top Healthcare Picks: Collegium Pharmaceutical (COLL), Adicet Bio (ACET)
Jefferies Analyst forecast on DE:354
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€44.41
Buy
100.06%
Upside
Reiterated
03/20/26
Jefferies Keeps Their Buy Rating on Collegium Pharmaceutical (COLL)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:354
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
€52.25
Buy
135.37%
Upside
Reiterated
09/21/26
H.C. Wainwright Reaffirms Their Buy Rating on Collegium Pharmaceutical (COLL)
Leerink Partners Analyst forecast on DE:354
Daniel Clark
Leerink Partners
Leerink Partners
€39.19
Buy
76.53%
Upside
Initiated
09/09/26
Leerink bullish on Collegium Pharmaceutical, initiates with an OutperformLeerink bullish on Collegium Pharmaceutical, initiates with an Outperform
Truist Financial Analyst forecast on DE:354
Alexander Xenakis
Truist Financial
Not Ranked
Truist Financial
€50.51→€42.67
Buy
92.22%
Upside
Initiated
09/09/26
Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (NASDAQ: COLL), Revolution Medicines (NASDAQ: RVMD) and Intellia Therapeutics (NASDAQ: NTLA)
Barclays Analyst forecast on DE:354
Jenna Davidner
Barclays
Barclays
€48.77→€41.8
Buy
88.29%
Upside
Reiterated
08/18/26
Barclays Sticks to Their Buy Rating for Collegium Pharmaceutical (COLL)
Piper Sandler Analyst forecast on DE:354
David Amsellem
Piper Sandler
Piper Sandler
€39.19→€37.45
Hold
68.68%
Upside
Reiterated
08/07/26
Piper Sandler Sticks to Their Hold Rating for Collegium Pharmaceutical (COLL)
Needham Analyst forecast on DE:354
Serge Belanger
Needham
Needham
€48.77→€40.06
Buy
80.45%
Upside
Reiterated
08/06/26
Analysts' Top Healthcare Picks: Collegium Pharmaceutical (COLL), Adicet Bio (ACET)
Jefferies Analyst forecast on DE:354
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€44.41
Buy
100.06%
Upside
Reiterated
03/20/26
Jefferies Keeps Their Buy Rating on Collegium Pharmaceutical (COLL)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
LGNDLigand Pharma
DNLIDenali Therapeutics
ACHVAchieve Life Sciences
PMNProMIS Neurosciences
CELCCelcuity
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Collegium Pharmaceutical

3 Months
Serge BelangerNeedham
Success Rate
12/24 ratings generated profit
50%
Average Return
+3.08%
Copying Serge Belanger's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +3.08% per trade.
1 Year
Serge BelangerNeedham
Success Rate
12/24 ratings generated profit
50%
Average Return
+3.70%
Copying Serge Belanger's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +3.70% per trade.
2 Years
Brandon FolkesH.C. Wainwright
Success Rate
11/25 ratings generated profit
44%
Average Return
-1.00%
Copying Brandon Folkes's trades and holding each position for 2 Years would result in 44.00% of your transactions generating a profit, with an average return of -1.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

354 Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
10
5
4
4
7
Buy
4
3
3
0
0
Hold
3
2
0
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
10
7
5
8
In the current month, 354 has received 7 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 354 average Analyst price target in the past 3 months is 42.24.
Each month's total comprises the sum of three months' worth of ratings.

354 Financial Forecast

354 Earnings Forecast

Next quarter’s earnings estimate for 354 is €1.57 with a range of €1.28 to €1.73. The previous quarter’s EPS was €1.65. 354 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 354 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 354 is €1.57 with a range of €1.28 to €1.73. The previous quarter’s EPS was €1.65. 354 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 354 has Performed in-line its overall industry.

354 Sales Forecast

Next quarter’s sales forecast for 354 is €187.39M with a range of €185.09M to €190.85M. The previous quarter’s sales results were €171.83M. 354 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 354 has Performed in-line its overall industry.
Next quarter’s sales forecast for 354 is €187.39M with a range of €185.09M to €190.85M. The previous quarter’s sales results were €171.83M. 354 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 354 has Performed in-line its overall industry.

354 Stock Forecast FAQ

What is DE:354’s average 12-month price target, according to analysts?
Based on analyst ratings, Collegium Pharmaceutical’s 12-month average price target is 42.24.
    What is DE:354’s upside potential, based on the analysts’ average price target?
    Collegium Pharmaceutical has 90.26% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Collegium Pharmaceutical a Buy, Sell or Hold?
          Collegium Pharmaceutical has a consensus rating of Strong Buy, which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Collegium Pharmaceutical’s share price target?
            The average share price target for Collegium Pharmaceutical is 42.24. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €52.25 ,and the lowest forecast is €37.45. The average share price target represents 90.26% Increase from the current price of €22.2.
              What do analysts say about Collegium Pharmaceutical?
              Collegium Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Collegium Pharmaceutical?
                To buy shares of DE:354, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.